Evidence mapPaperPMID 42268265Full record

ArticleMolecular oncology2026

MITF maintains genome stability in nonmelanocyte lineages.

Drifa H Gudmundsdottir, Adrián López García de Lomana, Thejus B Venkatesh, Kritika Kirty, Snaevar Sigurdsson, Linda Vidarsdottir, Ramile Dilshat, Erla Sveinbjornsdottir, Snaedis Ragnarsdottir, Daniel H Magnusson and 4 more

Abstract read
In one paragraph

Article in Molecular oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Drifa H GudmundsdottirCancer Research Laboratory, Faculty of Medicine, University of Iceland, Reykjavik, Iceland.ORCID https://orcid.org/0009-0001-6660-4961
Adrián López García de LomanaBiomedical Center, University of Iceland, Reykjavik, Iceland.
Thejus B VenkateshCancer Research Laboratory, Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
Kritika KirtyCancer Research Laboratory, Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
Snaevar SigurdssonBiomedical Center, University of Iceland, Reykjavik, Iceland.
Linda VidarsdottirCancer Research Laboratory, Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
Ramile DilshatBiomedical Center, University of Iceland, Reykjavik, Iceland.
Erla SveinbjornsdottirDepartment of Genetics and Molecular Medicine, University Hospital of Iceland, Reykjavik, Iceland.
Snaedis RagnarsdottirCancer Research Laboratory, Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
Daniel H MagnussonCancer Research Laboratory, Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
Maria R BustosCancer Research Laboratory, Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
Eirikur SteingrimssonCancer Research Laboratory, Faculty of Medicine, University of Iceland, Reykjavik, Iceland.ORCID https://orcid.org/0000-0001-5826-7486
Thorkell GudjonssonCancer Research Laboratory, Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
Stefan SigurdssonCancer Research Laboratory, Faculty of Medicine, University of Iceland, Reykjavik, Iceland.ORCID https://orcid.org/0000-0002-5284-0058

Funding

Rannís 163315-05Rannís 217768Rannís 228533-051The Icelandic Cancer Society Research Fund 2021The Icelandic Cancer Society Research Fund 2023
6 · The paper itself

Abstract

Microphthalmia-associated transcription factor (MITF) is crucial for development and survival of melanocytes and serves as a lineage-specific oncogene that is amplified in 10-20% of melanomas. The role of MITF in pathways maintaining genome integrity, such as DNA replication, DNA repair, and mitosis has been extensively studied in melanocytes. In addition to its pro-survival role in melanoma, recent studies have shown that MITF expression has important implications for cancer progression and treatment in other cancer types. Nevertheless, studies on the role of MITF in other tissues are scarce. Here, we show that depletion of MITF causes genome instability in nonmelanocytic cell lineages, which results in activation of P53, cell cycle arrest, and apoptosis. Moreover, we show that P53 activation in MITF-depleted cells is dependent on LATS2, a kinase with an established role in the Hippo pathway. Finally, we show that LATS2 mediated upregulation of P53 is ATR-dependent. Collectively, this study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage, which might contribute to the tumor suppressive function of MITF.

Indexed as

genome instabilityMITFreplication stress

Identifiers

PMID42268265
PMCPMC13398355

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.